AHCPR/DuPont Merck collaboration for Coumadin use in stroke prevention is agency's first with private sector.
DUPONT MERCK/AHCPR STROKE PREVENTION STUDY COLLABORATION will involve a three-year intervention study in managed care organizations to assess educational efforts aimed at physicians and patients on the appropriate use of the company's anticoagulant warfarin (Coumadin). Agency for Health Care Policy & Research Administrator Clifton Gaus unveiled the agreement, the HHS agency's first formal partnership with the private sector, at an April 30 press conference in Washington, D.C.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth